AssetID: 54674462
Headline: UNCAPTIONED: New Pill Rivals Ozempic in Weight and Sugar Control
Caption: New Pill Rivals Ozempic in Weight and Sugar Control. A new daily pill for weight loss has shown strong results in a major clinical trial. Participants taking 36mg of orforglipron lost an average of 7.3kg (16lbs) in 9 months. The drug also significantly lowered blood sugar—sometimes below diabetes thresholds. Developed by Eli Lilly, the pill was tested on 559 obese patients with type 2 diabetes. Unlike injectable drugs like Ozempic, orforglipron is a once-daily pill version of a GLP-1 agonist. The company says the pill met expectations for safety, tolerability, glucose control, and weight loss. Lower doses also showed benefits: a 3mg dose led to 4.5% weight loss, while 12mg yielded 5.8%. Experts say oral treatments like this could make weight and diabetes management more accessible. The full results will be presented in June and Eli Lilly plans to seek approval later this year. Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT
Keywords: Eli Lilly,Ozempic,Pill,Drug,Weight loos,Orforglipron,Diabetes,Type 2 diabetes,Clinical trial,Blood sugar,Weight,Injectable,Weight management,Glucose control
PersonInImage: